C.M. Bidwell & Associates’s Adaptive Biotechnologies ADPT Stock Holding History

C.M. Bidwell & Associates’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,070	Closed	-$168K	–	508
2023 Q1	$168K	Buy	19,070 +15,800	+483%	+$139K	0.13%	137
2022 Q4	$25K	Hold	3,270	–	–	0.02%	330
2022 Q3	$23K	Buy	+3,270	New	+$30.8K	0.02%	323
2022 Q1	–	Sell	-119	Closed	-$3K	–	528
2021 Q4	$3K	Hold	119	–	–	﹤0.01%	476
2021 Q3	$4K	Hold	119	–	–	﹤0.01%	464
2021 Q2	$5K	Buy	+119	New	+$4.63K	﹤0.01%	444

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

C.M. Bidwell & Associates's ADPT Position: Q2 2023 in Review

C.M. Bidwell & Associates sold out of Adaptive Biotechnologies (ADPT) in Q2 2023, closing a stake of 19,070 shares — an estimated $168K sold.

C.M. Bidwell & Associates first reported a position in ADPT in Q2 2021 and held it in 6 quarters. The position peaked at $168K in Q1 2023. 210 funds tracked by Wall St. Rank hold ADPT as of Q2 2023.

C.M. Bidwell & Associates reported no remaining Adaptive Biotechnologies position as of Q2 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 19,070 Adaptive Biotechnologies shares in Q2 2023, an estimated $168K.
C.M. Bidwell & Associates first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 6 quarters.
C.M. Bidwell & Associates's Adaptive Biotechnologies position peaked at $168K in Q1 2023.
210 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2023, filed 14 Aug 2023.